Ftse Mib
34.316,27
-0,17%
DAX
18.497,02
-0,55%
S&P 500
5.645,84
0,26%
NASDAQ
18.472,57
0,00%
Bitcoin
63.812,30
-1,60%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Europa EU Sanofi (SAN) Sanofi (SAN) Notizie

SAN

Sanofi (SAN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:SAN
DataOraFonteTitoloSimboloCompagnia
27/01/202307:00GlobeNewswire Inc.Communiqué de presse: Le CHMP recommande l’extension des indications de Dupixent® (dupilumab) dans l’UE au traitement de la dermatite atopique sévère du jeune enfant à partir de 6 moisEU:SANSanofi
27/01/202307:00GlobeNewswire Inc.Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitisEU:SANSanofi
25/01/202323:30GlobeNewswire Inc.Communiqué de presse : Le NEJM publie des données de phase III sur l’efanesoctocog alpha une fois par semaine qui illustrent son potentiel à transformer le traitement de l’hémophilie AEU:SANSanofi
25/01/202323:30GlobeNewswire Inc.Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia AEU:SANSanofi
17/01/202320:44GlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions – Decembre 2022EU:SANSanofi
17/01/202320:44GlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares – December 2022EU:SANSanofi
11/01/202317:30GlobeNewswire Inc.Press Release: Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750MEU:SANSanofi
11/01/202317:30GlobeNewswire Inc.Communiqué de presse: Sanofi Ventures annonce un engagement de capital pluriannuel de la part de Sanofi, qui portera à 750 millions de dollars le capital de son fonds evergreenEU:SANSanofi
05/01/202308:55Dow Jones NewsSanofi, AstraZeneca Respiratory Treatment Nirsevimab Biologics License Accepted by FDAEU:SANSanofi
05/01/202308:46Dow Jones NewsSanofi : la FDA va examiner la demande de licence pour le nirsevimabEU:SANSanofi
05/01/202308:00GlobeNewswire Inc.Communiqué de presse: La FDA accepte d’examiner la demande de licence pour le nirsevimab, première option de protection contre le VRS pour tous les nourrissonsEU:SANSanofi
05/01/202308:00GlobeNewswire Inc.Press Release: FDA accepts nirsevimab application as first protective option against RSV disease for all infantsEU:SANSanofi
04/01/202308:41Dow Jones NewsSanofi anticipe des effets de change positifs au quatrième trimestreEU:SANSanofi
04/01/202307:30GlobeNewswire Inc.Communiqué de presse: Mise en ligne du document «Q4 2022 Memorandum for modelling purposes»EU:SANSanofi
04/01/202307:30GlobeNewswire Inc.Press Release: Availability of the Q4 2022 Memorandum for modelling purposesEU:SANSanofi
03/01/202309:36Dow Jones NewsUn début d'année à haute intensité attend les grandes entreprises françaises -DJ PlusEU:SANSanofi
21/12/202223:30GlobeNewswire Inc.Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of MedicineEU:SANSanofi
21/12/202223:30GlobeNewswire Inc.Communiqué de presse: Dupixent® (dupilumab) : publication de résultats positifs de phase III chez l’adulte et l’adolescent atteints d’œsophagite à éosinophiles dans le New England Journal of MedicineEU:SANSanofi
19/12/202208:25Dow Jones NewsSanofi et Innate Pharma étendent leur collaboration en oncologie avec les cellules NKEU:SANSanofi
19/12/202207:00GlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions Novembre 2022EU:SANSanofi
19/12/202207:00GlobeNewswire Inc.Communiqué de presse: Sanofi et Innate Pharma étendent leur collaboration sur les anticorps thérapeutiques engageant les cellules Natural Killer en oncologieEU:SANSanofi
19/12/202207:00GlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares November 2022EU:SANSanofi
19/12/202207:00GlobeNewswire Inc.Press Release: Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncologyEU:SANSanofi
16/12/202214:23Dow Jones NewsRegeneron, Sanofi Get CHMP Backing for Dupixent in Eosinophilic EsophagitisEU:SANSanofi
16/12/202214:16Dow Jones NewsSanofi: le CHMP recommande l'approbation du Dupixent contre l'œsophagite à éosinophilesEU:SANSanofi
16/12/202213:30GlobeNewswire Inc.Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitisEU:SANSanofi
16/12/202213:30GlobeNewswire Inc.Communiqué de presse: Le CHMP recommande l’approbation de Dupixent® (dupilumab) dans l’UE pour le traitement de l’œsophagite à éosinophilesEU:SANSanofi
15/12/202207:40Dow Jones NewsSanofi: Bruxelles approuve Dupixent pour traiter le prurigo nodulaireEU:SANSanofi
15/12/202207:00GlobeNewswire Inc.Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularisEU:SANSanofi
15/12/202207:00GlobeNewswire Inc.Communiqué de presse: Dupixent® (dupilumab) : premier et seul médicament ciblé approuvé par la Commission européenne pour le traitement du prurigo nodulaireEU:SANSanofi
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:SAN

La tua Cronologia

AMEX
IBDR
iShares iBonds Dec 2026 ...
LSE
BIDS
Bidstack
NASDAQ
SONO
Sonos
LSE
KIBO
Kibo Energy
LSE
0EKN
Union Hoteli Dd
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network